Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. The company was founded in 2017 and is headquartered in Bethesda, Maryland.

Gain Therapeutics Inc.

The latest announcement is out from Gain Therapeutics ( ($GANX) ). Gain Therapeutics, Inc., a company involved in the sale of common stock, announc...

Market Cap	$74.41M	P/E Ratio	N/A
52W High	$4.34	52W Low	$1.41
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	13.4%	52W Position	93.2%
Overall Score	57	Value Score	40
Quality Score	31	Technical Score	100

EPS Current Est	$-0.64	EPS Next Est	$-0.63
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GANX	$4.14	+0.73%	1.84M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GANX	$4.14	+0.7%	1.84M
3
4
5
6

GANX

GANX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Gain Therapeutics Inc. Data in Excel

Get Gain Therapeutics Inc. Data in Excel